A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, hematology, emergency medicine ...
In 2019, approximately 40% of oncology patients in the United States were eligible for treatment with immune checkpoint inhibitors (ICIs). Furthermore, it is estimated that one in seven patients who ...
An interview with Dr. Bryan Schneider from the University of Michigan Health System and Dr. Kathryn Bollin from Scripps MD Anderson Cancer Center, co-chairs of the Management of Immune-Related Adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results